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The prevalence of coronary artery disease in patients with
chronic kidney disease (CKD) is high, and acute myocardial
infarction contributes significantly to the steep mortality rate
in this population. Diagnosing an acute coronary syndrome
in these patients is often difficult though essential.
Traditional diagnostic tools such as symptoms and
electrocardiographic manifestations are not entirely helpful
in patients with CKD, and physicians are often left to rely on
laboratory analysis of biomarkers such as cardiac troponin.
However, troponin levels are increased in patients with renal
failure in the absence of clinical myocardial ischemia, making
their interpretation problematic. Several theories have been
proposed for the mechanism of elevated troponin levels in
CKD. Irrespective of our uncertainty regarding mechanism,
studies have shown that there is a strong prognostic
implication of elevated troponin levels; and that it is
predictive of increased risk of mortality and cardiovascular
events. Troponin levels rise over 6–8 h in the setting of acute
myocardial injury; hence, it is imperative to obtain these
levels sequentially in patients with CKD in whom a clinical
cardiac event is suspected. A distinct rise and fall in the levels
over baseline strongly support the diagnosis of acute
myocardial necrosis. Despite uncertainties regarding
increased troponins in patients with CKD, their value remains
clear.
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Despite the advances in the diagnosis and treatment of
coronary artery disease, the 5-year survival for dialysis
patients is 33–34%. Death from acute myocardial infarction
contributes to about half of those cases, with the mortality
rate being highest in the first 6 months.1 The prevalence of
coronary artery disease in this population is alarmingly high,
and up to 38–62.5% of patients have significant stenosis.2,3 Of
this group, the majority of the patients have multivessel
disease. Often the first manifestation of atherosclerosis in a
patient with chronic kidney disease (CKD) is sudden cardiac
death or acute myocardial infarction, making it crucial to
diagnose cardiac ischemia effectively.
Cardiac enzymes such as creatine kinase, creatine kinase-
MB, and myoglobin have been used for the detection of early
myocardial necrosis for many years. However, these biomar-
kers are well known to be increased in patients with CKD and
can be misleading.4 With the introduction of cardiac
troponins T and I (cTnT and cTnI) came more specificity,
but interpretation of troponins in the setting of CKD is also
problematic.4,5
It has been clearly established that troponin levels are
increased in patients with renal failure, even in the absence of
clinically suspected myocardial ischemia.5,6 Several mechan-
isms have been proposed for this increase, although no
definite explanation exists.
Initial reports documented that up to 71% of patients
with CKD had elevated cTnT in the absence of clinical
evidence for acute ischemia.4 The original explanation was
that uremia induced skeletal muscle expression of cTnT. This
mechanism has now been disproven, and the increased
troponin levels have been attributed to the imprecision of
first-generation assays that were used to detect cTnT. The
detection antibody used in the assay crossreacted with
skeletal muscle TnT, thereby displaying higher blood levels.7
As a result, second-generation assays were developed with a
crossreactivity of o0.01% with skeletal muscle TnT, and
currently third-generation assays exist in which recombinant
human cTnT is used as the material standard. Despite the
newer generation assays, we still find that cTnT remains
elevated to a higher degree than cTnI in patients with CKD.
In fact, up to 53% of patients with CKD have elevated cTnT
and 17% have elevated cTnI in the absence of clinical acute
myocardial necrosis.8,9
One common misconception is that reduced clearance of
troponin contributes to the elevated levels in patients with
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CKD. However, this is improbable as these are very large
molecules and unlikely to be cleared by the kidneys. cTnT has
a molecular weight of 37 kDa and that of cTnI is 22.5 kDa.
cTnI is released from the cell in complexes of TnT-I-C
(77 kDa) and TnI-C (40 kDa), while cTnT is released as free
TnT or TnT-I-C complexes.4 Recent studies have shown that
both cTnT and cTnI are degraded into fragments in the
myocardial cell and then released as small molecules that are
still detected by the assays.10 Diris et al.10 demonstrated that
cTnT is split into fragments that range in size from 8 to
25 kDa, even in samples with measured cTnT concentrations
that are less than 0.01 mg/l. These fragments are small enough
to be cleared by the kidneys, and therefore could be elevated
in patients with renal failure owing to delayed clearance. As
these small fragments are measured by the assay, they could
account for the elevated troponin level reported in patients
with CKD. The immunoassays may not only detect the
proteolytic degradation products of the troponins but also
the covalently bound troponin complexes.
In both patients with and without CKD, it is not
uncommon to observe an elevated troponin level in the
absence of elevated creatine kinase and creatine kinase-MB
levels following unstable angina and after post-percutaneous
coronary interventions.6 As the cardiac troponins T and I are
specific to the heart, most have assumed that there has to be
myocardial necrosis in order to detect circulating troponin.
Can circulating troponin be increased in the blood in the
absence of myocardial necrosis? This is not the case with
creatine kinase or creatine kinase-MB, but might be true of
troponin. Wu et al.11 have proposed the concept of reversible
myocardial ischemic release. Since creatine kinase and
creatine kinase-MB levels correlate with the severity of
myocardial necrosis, and have been shown to be released
when total coronary artery occlusions in dogs exceed 30 min,
these enzymes are released only when irreversible injury
occurs.11 There is general agreement on this point. There is
still some uncertainty, however, whether troponin can be
released from an injured but still viable myocardial cell.
In actuality, only 7% of cTnT and 3.5% of cTnI exists
freely in the cardiac myocyte cytoplasm.4,6 The majority of
the cardiac troponins are bound to contractile proteins in the
sarcomere. In the setting of acute myocardial injury, the free
cytosolic cardiac troponins are possibly released earlier, and
may be elevated despite normal levels of creatine kinase and
creatine kinase-MB. It is also possible that uremia augments
the free serum concentration and clearance of the cardiac
troponins and their fragment subunits, but this has not been
proven.
Ischemia and subsequent reperfusion may cause the
proteolytic products of troponin to increase dramatically,
causing a more rapid egress from the cells.12 There is
evidence that TnI degradation products are detected in a
short ischemic interval of 15 min. Apoptosis does not appear
to release troponin from the cell. Only necrosis and possibly
reversible ischemic injury release troponin from cardiac
myocytes.
Not everyone agrees with the theory of reversible ischemic
release of troponins. In a study where patients underwent
exercise stress thallium testing, there was no increase in
troponin levels in patients with demonstrable evidence of
cardiac ischemia.11 Perhaps there is a physiologic egress
of these proteolytic products with a continuous micro-loss of
cardiac myocytes from the normal heart.12 This may be more
noticeable in patients with CKD owing to reduced clearance
of the small troponin fragments.
There are other possible mechanisms of elevated troponin
levels in patients with CKD. For instance, one mechanism
may be the occurrence of subclinical myocyte damage from
micro-infarctions.4,6 Increased circulating troponin levels
have also been detected in the presence of left ventricular
hypertrophy in the absence of acute myocardial ischemia.8,13
It is not uncommon to observe left ventricular hypertrophy
in patients with CKD. It may be that the release of troponins
in the hypertrophied heart may be somewhat different,
reflecting changes in myocardial protein turnover or
impaired cell membrane permeability.6,13
A similar scenario in which elevated troponin levels exist
without clinically suspected myocardial injury is in the
presence of congestive heart failure (CHF).6 Approximately
25–33% of patients with CHF have elevated cTnT levels.6
Studies have documented that the increased levels correlate
with the severity of heart failure, and also serve as a
prognostic marker.14 This too may be due to continuing
myocardial necrosis. Patients with CKD are more likely to
develop CHF, and frequently develop the cardio-renal
syndrome. Additionally, the glomerular filtration rate
in patients with CHF can be decreased, and it could be
that small troponin fragments are not being cleared by the
kidney.
It is important to recognize that despite the several
theories of why troponin levels are elevated in patients with
CKD, the significance of this finding should not be easily
dismissed. Numerous studies have shown that there is a
strong prognostic implication of elevated troponin levels in
cardiology patients and in patients with CKD. Elevated cTnT
and cTnI have both been shown to be predictive of increased
risk of mortality and cardiovascular disease events.7,8,15,16 An
analysis from the GUSTO-IV ACS trial showed that the
combination of renal failure and levels of cTnT40.1 ng/ml
additionally increases the risk of death and myocardial
infarction at 30 days.15 Elevated troponin levels in otherwise
stable patients with CKD is associated with a 2–5-fold
increased risk of death, both in the short and long term.16
Diris et al.10 demonstrated that the troponin levels increases
with the extent of dialysis duration. Another study by
Fernandez-Reyes et al.8 showed that troponin levels tend to
increase over time while a patient remains on dialysis. This
may be due to increasing prevalence of left ventricular
hypertrophy or CHF. Another important finding they
reported was that the risk of ischemic heart disease remains
low for patients with CKD who have stable and persistent
cTnT levelso0.1 ng/ml.
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It is not rare for physicians, particularly cardiologists,
nephrologists, and emergency physicians, to encounter a
dialysis patient with an elevated troponin level, and to be
asked whether an acute coronary syndrome is occurring.
Diagnosing this is essential, as there are many implications to
treatment and therapy. Often, we are left to rely on laboratory
analysis, since as many as a quarter of these patients will have
silent ischemia.17 Additionally, the presence of left ventricular
hypertrophy, uremic pericarditis, and electrolyte abnormal-
ities may obscure electrocardiographic manifestations of
ischemia.
In the setting of an acute myocardial injury, troponin
levels rise over 6–8 h and remain elevated for up to 10 days.
Therefore, it is imperative to obtain sequential troponin
levels; the observation of a distinct rise and fall in the levels
over the baseline, in the clinical context of acute myocardial
injury, would be strongly supportive of acute myocardial
necrosis. Although there are no clear guidelines for using
cutoff values for troponin, Van Lente et al.18 recommended
that a higher threshold of 0.5 mg/l for cTnT should be used to
predict adverse events in patients with renal insufficiency and
acute coronary syndrome.
Recently, additional work has been conducted on the
utility of a multi-biomarker approach for risk stratification in
CKD. The combination of increased levels of cTnT and
C-reactive protein was associated with increased risk of
death.8,19 Apple et al.20 looked at N-terminal pro-B-type
natriuretic peptide (NT-proBNP), high-sensitivity C-reactive
protein, cTnT, and cTnI. They demonstrated that the
biomarkers provided predictive power both individually
and in combination.
The cardiac troponins have assisted our ability to detect
and diagnose acute coronary syndrome. In patients with
CKD, their value is still clear despite documented baseline
elevations. Not only do they provide prognostic information
and aid in the risk stratification process, but rising levels
when measured sequentially can be suggestive of acute
myocardial necrosis. Troponin levels can be elevated in other
situations such as CHF, pulmonary embolism, sepsis, and in
marathon runners.6 Currently, there is a move towards
identifying other novel biomarkers for detection of ischemia
and risk stratification in acute coronary syndrome. Examples
of these include markers of plaque destabilization, such as
myeloperoxidase, matrix metalloproteinases (MMP-9); mar-
kers of plaque rupture, such as soluble CD40 ligand,
pregnancy-associated plasma protein A; and markers of
ischemia such as choline and ischemia-modified albumin.21
However, more studies are warranted to confirm their
validity, particularly in patients with CKD. Biomarkers are
becoming increasingly a part of diagnostic medicine. Correct
interpretation will require a better understanding of their
cellular source, synthesis, cellular egress, and clearance from
the circulation.
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